AAAAAA

   
Results: 1-8 |
Results: 8
Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma - a phase 1 study
Authors: Trudel, S Li, Z Dodgson, C Nanji, S Wan, Y Voralia, M Hitt, M Gauldie, J Graham, FL Stewart, AK
Citation: S. Trudel et al., Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma - a phase 1 study, LEUKEMIA, 15(5), 2001, pp. 846-854
Assessment of patient waiting times for vascular surgery
Authors: Turnbull, RG Taylor, DC Hsiang, YN Salvian, AJ Nanji, S O'Hanley, G Doyle, DL Fry, PD
Citation: Rg. Turnbull et al., Assessment of patient waiting times for vascular surgery, CAN J SURG, 43(2), 2000, pp. 105-111
Retroviral-mediated transfer and expression of the multidrug resistance protein 1 gene (MRP1) protect human hematopoietic cells from antineoplastic drugs
Authors: Omori, F Juopperi, T Chan, CK Chang, YN Phipps, S Nanji, S Zhao, YJ Stewart, AK Dube, ID
Citation: F. Omori et al., Retroviral-mediated transfer and expression of the multidrug resistance protein 1 gene (MRP1) protect human hematopoietic cells from antineoplastic drugs, J HEMATH ST, 8(5), 1999, pp. 503-514
Gene therapy for canine alpha-L-iduronidase deficiency: In utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease
Authors: Lutzko, C Omori, F Abrams-Ogg, ACG Shull, R Li, LH Lau, K Ruedy, C Nanji, S Gartley, C Dobson, H Foster, R Kruth, S Dube, ID
Citation: C. Lutzko et al., Gene therapy for canine alpha-L-iduronidase deficiency: In utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease, HUM GENE TH, 10(9), 1999, pp. 1521-1532
Engraftment of gene-marked hematopoietic progenitors in myeloma patients after transplant of autologous long-term marrow cultures
Authors: Stewart, AK Sutherland, DR Nanji, S Zhao, Y Lutzko, C Nayar, R Peck, B Ruedy, C McGarrity, G Tisdale, J Dube, ID
Citation: Ak. Stewart et al., Engraftment of gene-marked hematopoietic progenitors in myeloma patients after transplant of autologous long-term marrow cultures, HUM GENE TH, 10(12), 1999, pp. 1953-1964
Adoptive transfer of genetically modified human hematopoietic stem cells into preimmune canine fetuses
Authors: Omori, F Lutzko, C Abrams-Ogg, A Lau, K Gartley, C Dobson, H Nanji, S Ruedy, C Singaraja, R Li, LH Stewart, AK Kruth, S Dube, ID
Citation: F. Omori et al., Adoptive transfer of genetically modified human hematopoietic stem cells into preimmune canine fetuses, EXP HEMATOL, 27(2), 1999, pp. 242-249
Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-gradenon-Hodgkin's lymphoma
Authors: Buckstein, R Imrie, K Spaner, D Potichnyj, A Robinson, JB Nanji, S Pennel, N Reis, M Pinkerton, P Dube, I Hewitt, K Berinstein, NL
Citation: R. Buckstein et al., Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-gradenon-Hodgkin's lymphoma, SEMIN ONCOL, 26(5), 1999, pp. 115-122
Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency
Authors: Lutzko, C Kruth, S Abrams-Ogg, ACG Lau, K Li, LH Clark, BR Ruedy, C Nanji, S Foster, R Kohn, D Shull, R Dube, ID
Citation: C. Lutzko et al., Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency, BLOOD, 93(6), 1999, pp. 1895-1905
Risultati: 1-8 |